Mevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/in Clinical Trial, Metastatic, Phase 2/by MaxNezastomig (REGN5678): New Drug Combo Shows Promise In mCRPC, But Safety Is A Concern
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxUPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025